| Trial ID: | L7173 |
| Source ID: | NCT01439854
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Study of Dapagliflozin on Mitochondrial Dysfunction and Impaired Insulin Signaling/Action
|
| Acronym: |
DAPA MITO
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT01439854/results
|
| Conditions: |
Insulin Sensitivity|Multiple Mitochondrial Dysfunctions Syndrome
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Change in Insulin Sensitivity, The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline. This is measured using TGD (whole body tissue glucose disposal)/SSPI (steady state plasma insulin concentration) ratio, baseline, two weeks | Secondary: Change in Mitochondrial Function, The change in mitochondrial function/gene expression at two weeks compared to baseline. This was measured by energy expenditure., baseline, two weeks
|
| Sponsor/Collaborators: |
Sponsor: The University of Texas Health Science Center at San Antonio | Collaborators: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
18
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-03
|
| Completion Date: |
2018-06-30
|
| Results First Posted: |
2019-10-29
|
| Last Update Posted: |
2019-10-29
|
| Locations: |
Diabetes Division, UTHSCSA, San Antonio, Texas, 78229, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01439854
|
